Treats metastatic non-small cell lung cancer (NSCLC). ANDA 209267, held by Hetero Labs. Erlotinib Hydrochloride.
As of Nov 22, 2026, ANDA 209267 (Erlotinib Hydrochloride), held by Hetero Labs, was first approved by FDA on May 24, 2024, with 0 approved supplements and 0 published complete response letters.
Erlotinib tablets are a kinase inhibitor indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 24, 2024 | Original application | Approved | None posted |
| Erlotinib HydrochlorideEQ 25MG BASE · tablet;oral | Erlotinib Hydrochloride | Rx |
| Erlotinib HydrochlorideEQ 100MG BASE · tablet;oral | Erlotinib Hydrochloride | Rx |
| Erlotinib HydrochlorideEQ 150MG BASE · tablet;oral | Erlotinib Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters